Notice of Special Interest (NOSI): Administrative Supplement Program to Help Develop Alzheimers-Focused NIH Grants
Notice NOT-AG-23-032 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 22, 2023 Category: Research Source Type: funding
Notice of Early Expiration of NOT-AG-23-015, "Notice of Special Interest (NOSI): Alzheimers-Focused Administrative Supplements for NIH Grants that are Not Focused on Alzheimers Disease"
Notice NOT-AG-23-031 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 22, 2023 Category: Research Source Type: funding
Simultaneous and Synergistic Multi-Target Validation for Alzheimers Disease-Related Dementias (R61/R33 Clinical Trial not allowed)
Funding Opportunity PAR-23-195 from the NIH Guide for Grants and Contracts. The ultimate goal is to develop multi-target disease-modifying therapeutics based on an appreciation of the complex interaction of pathways, cells, circuits, systems or pathologies that are present in complex AD/ADRD diagnoses. Such therapeutics could be a single drug or biologic targeting multiple pathways, cell, circuits, systems or pathologies, or could be a combination of therapies. While hundreds of possible targets have been suggested for AD alone, theres a need to better understand how multiple targets might interact in a synergistic way ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 20, 2023 Category: Research Source Type: funding
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
Funding Opportunity PAR-23-207 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 14, 2023 Category: Research Source Type: funding
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
Funding Opportunity PAR-23-208 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advanceadavnce mechanistic understanding of both biobehavioral and neurobiologfical pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the develo...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 14, 2023 Category: Research Source Type: funding
Limited Competition: National Health and Aging Trends (NHATS) and National Study of Caregiving (NSOC) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-24-037 from the NIH Guide for Grants and Contracts. The purpose of this limited competition Request for Applications (RFA) is to continue data collection, development, and dissemination of the National Health and Aging Trends Study (NHATS) and National Study of Caregiving (NSOC). Continuation of the study requires both knowledge of, and access to, the NHATS and NSOC sample frames. Therefore, this RFA is limited to investigators and institutions with access to the NHATS and NSOC sample frame, as the frame will be used to contact and collect new data from participants. This RFA aims to provide a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 9, 2023 Category: Research Source Type: funding
Notice of Intent to Publish a Funding Opportunity Announcement for Role of Environmental Stress in the Health Inequities of Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)
Notice NOT-NS-23-087 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 5, 2023 Category: Research Source Type: funding
Enhancing Use of Harmonized Cognitive Assessment Protocol Data?(R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-24-032 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to further our understanding of how different behavioral, social, cultural, environmental, and institutional factors affect the trajectory of cognitive aging and Alzheimers disease (AD) and AD-related dementias (AD/ADRD) and the experience of living with or managing AD/ADRD in different national or regional contexts. Specifically, NIA seeks to support analyses of data from the Harmonized Cognitive Assessment Protocol (HCAP) from the US or another country where HCAP data is available ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 31, 2023 Category: Research Source Type: funding
Notice of Change to RFA-AG-24-009, "Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Real-World Data Platform (U54 Clinical Trial Optional)"
Notice NOT-AG-23-028 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 19, 2023 Category: Research Source Type: funding
Preclinical Studies to Characterize the Impact of Toxicants on Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-24-023 from the NIH Guide for Grants and Contracts. The central goal of this funding initiative is to evaluate the molecular, pathologic and functional consequences of major toxicants known to be associated with elevated AD/ADRD risk, in mouse models of Late Onset AD (LOAD). Projects funded through this program will examine the consequences of early and mid-life exposure on late-life brain health by conducting cross-sectional/longitudinal multi-modal phenotyping (molecular, biochemical, pathologic and behavioral) of mouse models of LOAD, and the impact of genetic diversity and sex-differences ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 15, 2023 Category: Research Source Type: funding
Quantifying the Impact of Environmental Toxicants on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Risk in Cohort Studies (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-24-022 from the NIH Guide for Grants and Contracts. This funding opportunity announcement will support research focused on major toxicants observed to be associated with elevated AD risk, and health disparities in AD-related pathologic and clinical outcomes. This funding opportunity aims to enrich existing longitudinal cohorts with measures of exposures to individual toxicants or combinations of toxicants and/or multi-omics molecular profiling that reflects the bodys response to exposure(s), support the development of multi-disciplinary teams needed for the rigorous measurement and assessment ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 15, 2023 Category: Research Source Type: funding
Understanding Gene-Environment Interactions in Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-24-021 from the NIH Guide for Grants and Contracts. The ?objective of this funding initiative is to stimulate research to gain mechanistic insights into gene-environment (GxE) interactions in response to environmental toxicants using human cell-based models. This RFA will support interdisciplinary research projects that utilize disease relevant human cell-based in vitro and ex vivo models to characterize the effects of gene environment interactions on gene regulation and cellular functions, and to elucidate toxicant mediated molecular and cellular mechanisms in brain aging and AD/ADRD. (Source...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 15, 2023 Category: Research Source Type: funding
Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-24-010 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy dis...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 15, 2023 Category: Research Source Type: funding
Notice of Special Interest (NOSI): Alzheimers-Focused Administrative Supplements for NIH Grants that are Not Focused on Alzheimers Disease
Notice NOT-AG-23-015 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 4, 2023 Category: Research Source Type: funding
Center without Walls for PET Ligand Development for Alzheimer's disease-related dementias (ADRDs) (U19 - Clinical Trial Optional)
Funding Opportunity RFA-NS-24-011 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports the development of PET radioligands that identify proteinopathies or pathological processes associated with the human biology of Alzheimer's disease related dementias (ADRDs). Activities supported under this FOA include, but are not limited to the in vitro screening of existing ligands against human ADRD brain tissue, medicinal chemistry support for development of new compounds and improvement of existing ligand specificity and selectivity, initial screening of ligands in appropriate animal...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 3, 2023 Category: Research Source Type: funding
